Registered Botswana · BoMRA

RANCLAV 1G

Clavulanic Acid 125 mg

BOT0701095 TABLETS 125 mg

What it does

Clavulanic acid is a substance that helps antibiotics work better by preventing certain bacteria from becoming resistant to treatment.

Commonly used for: infections caused by bacteria, bacterial infections (e.g., pneumonia, bronchitis)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
BOT0701095
Registration date
2007-11-16
Expiry date
2030-06-25
Status
Registered/Compliant
Active ingredient
Clavulanic Acid 125 mg
Dosage form
TABLETS
Strength
125 mg
Pack size
-
Therapeutic class
-
RxNorm RxCUI
48203
Manufacturer / MAH
Sun Pharmaceuticals Industries
Country of origin
India
Manufacturer location
CTS, 1, SUN HOUSE, No. 201 B, Western Express Hwy, Geetanjali Railway Colony, Ram Nagar, Goregaon East, Mumbai, Maharashtra 400063, India

Source: Botswana Medicines Regulatory Authority · fetched 2026-09-18 04:32:37

Disclaimer: This information is sourced from Botswana Medicines Regulatory Authority (Botswana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Clavulanic acid is a substance that helps antibiotics work better by preventing certain bacteria from becoming resistant to treatment.

What it treats

  • infections caused by bacteria
  • bacterial infections (e.g., pneumonia, bronchitis)

How it works

It works by blocking enzymes that bacteria produce to resist antibiotics, making the antibiotics more effective.

Who it's for

It is used for adults and children who have bacterial infections that need antibiotic treatment.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: clavulanic

Clavulanic acid is a beta-lactamase inhibitor that is often combined with penicillin antibiotics to enhance their efficacy against beta-lactamase-producing bacteria. It is structurally related to penicillins and prevents the hydrolysis of beta-lactam antibiotics, thereby extending their spectrum of activity. Clavulanic acid itself has minimal antibacterial activity but is crucial in overcoming antibiotic resistance.

Indications

  • Infections caused by beta-lactamase-producing bacteria
  • Acute bacterial sinusitis
  • Acute otitis media
  • Lower respiratory tract infections
  • Urinary tract infections

Dosage

Children: Refer to the BNF for Children for specific dosing according to age and weight; adjustments may be necessary based on the clinical scenario.

Adults: Refer to specific product guidelines for dosing; typical regimens depend on the combination antibiotic used and the severity of the infection.

Mechanism of action

Clavulanic acid works by irreversibly binding to the active site of beta-lactamase enzymes that are produced by certain bacteria to inactivate beta-lactam antibiotics. By inhibiting these enzymes, clavulanic acid protects the penicillin antibiotic from degradation, allowing it to exert its antibacterial effects.

Pharmacodynamics

Clavulanic acid has a synergistic effect when combined with other antibiotics, particularly amoxicillin. The presence of clavulanic acid allows for the effective treatment of infections caused by bacteria that would otherwise be resistant to penicillins. Its antibacterial activity is generally weak on its own but significantly enhances the efficacy of other beta-lactam antibiotics.

Pharmacokinetics

Clavulanic acid is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 hour. It is widely distributed throughout the body and has a half-life of approximately 1 hour. The drug is primarily excreted unchanged in the urine. In the presence of renal impairment, dosage adjustment may be necessary, as the elimination of clavulanic acid can be affected.

Contra-indications

  • Hypersensitivity to clavulanic acid or any of the excipients
  • History of jaundice or hepatic impairment associated with previous use of penicillins or beta-lactam antibiotics

Adverse effects

  • Nausea
  • Diarrhea
  • Rash
  • Elevated liver enzymes
  • Allergic reactions including anaphylaxis
  • Superinfection

Interactions

  • May enhance the effects of anticoagulants such as warfarin
  • Probenecid may increase plasma concentrations of clavulanic acid
  • May reduce the efficacy of oral contraceptives

Precautions

  • Caution in patients with renal impairment
  • Monitor liver function in patients receiving prolonged therapy
  • Use with caution in patients with a history of allergic reactions to beta-lactams

Pregnancy

Clavulanic acid is categorized as pregnancy category B. Animal studies have not shown any harm to the fetus, but there are no adequate and well-controlled studies in pregnant women.

Breast-feeding

Clavulanic acid is excreted in breast milk, but it is generally considered safe for use during breastfeeding. Monitor for potential effects in the infant.

Storage

Store at room temperature, away from moisture and heat. Protect from light. Keep out of reach of children.

Formulations

  • Oral tablets
  • Oral suspension
  • Injectable forms

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.